

INAUGURAL MDIP CONFERENCE 2021

TITLE	SUBMISSIONS
Exploring variation in biomarker testing within routine clinical cancer care.	We welcome submissions on approaches to explore variation and broker better access to biomarker testing for cancer patients.
The role of the oncologist/pathologist in selecting the right test for the right cancer patient at the right time.	We welcome submissions that explore the challenges of selecting the most informative biomarker test for each patient, based on their cancer type and treatment history.
Working with payors to ensure that biomarker tests are reimbursed in the private and public healthcare sectors.	We welcome submissions on approaches that reduce patients paying out of pocket for biomarker testing in the private sector and expand the breadth of biomarker testing that is reimbursed in the NHS.
The role of the MDT in interpreting results from complex biomarker assays, in order to signpost patients to optimum treatment choices.	We welcome the presentation of projects that have been organised to support the annotation of complex biomarker reports, turning them into actionable clinical information that the MDT can use to guide treatment choices for their cancer patients.
Putting the patient at the centre of the decision making process.	We welcome submissions from patients, advocates and clinical teams describing their approach to empowering patients to take an active role in their cancer care.
Educating the clinical community and patients to discuss biomarker testing at every stage of the patient's cancer journey.	We welcome submissions from individuals who are leading the education of clinical teams and patients, with a focus on personalised medicine, at the patient, MDT, organisation or system level.
Evidencing the case for biomarker testing in routine clinical care and measuring outcomes.	We welcome submissions from those leading studies or wishing to establish a study to examine the financial case for more widespread use of biomarker testing in cancer, and investigating the impact on clinical outcomes.
Optimising tissue pathways to ensure availability of material for biomarker testing.	We welcome submissions describing projects examining the most efficient use of tumour biopsies, such as optimising diagnostic procedures (surgical and radiological) and streamlining pathology tissue pathways, to ensure that adequate material is available for appropriate biomarker testing.
Increasing therapeutic options by expanding access to clinical trials.	We welcome submissions from teams and organisation who are committed to improving access to oncology clinical trials through the use of biomarker profiling.